4//SEC Filing
Serafin Andrew 4
Accession 0001821460-26-000002
CIK 0001802665other
Filed
Jan 25, 7:00 PM ET
Accepted
Jan 26, 4:48 PM ET
Size
19.4 KB
Accession
0001821460-26-000002
Research Summary
AI-generated summary of this filing
Harmony (HRMY) Chief Strategy Officer Exercises Options; Shares Withheld
What Happened
- Andrew Serafin, Chief Strategy Officer at Harmony Biosciences (HRMY), exercised/options-converted a total of 5,100 shares (2,500 on 2026-01-24 and 2,600 on 2026-01-25) reported at an exercise/conversion price of $0.00. To satisfy tax withholding, the issuer withheld 1,116 shares (Jan 24) and 1,126 shares (Jan 25) at $36.82 each, totaling $41,091 and $41,459 respectively (combined ~$82,550).
- The filing also reports awards of restricted stock units (RSUs) totaling 54,800 shares (42,600 and 12,200) on 2026-01-22, reported as derivative awards (no cash paid). The RSUs and option vesting are subject to multi-year schedules described in the footnotes.
Key Details
- Transaction dates and amounts:
- 2026-01-22: RSU grants — 42,600 and 12,200 RSUs (acquired, $0.00; derivative awards).
- 2026-01-24: Option exercise/conversion — 2,500 shares (exercise price $0.00); 1,116 shares withheld for taxes at $36.82 = $41,091.
- 2026-01-25: Option exercise/conversion — 2,600 shares (exercise price $0.00); 1,126 shares withheld for taxes at $36.82 = $41,459.
- Net shares retained from exercises (after withholding): 5,100 exercised − 2,242 withheld = 2,858 net shares issued to the reporting person.
- Shares owned after the transactions: not specified in the provided data.
- Notable footnotes:
- F1: Shares were withheld by the issuer to satisfy required income tax withholdings on RSU vesting/exercise.
- F2–F5: Vesting schedules — one stock option vests 25% on Jan 22, 2027, then quarterly thereafter; RSUs vest in four equal annual installments beginning on specified dates (Jan 22, 2027; Jan 24, 2025; Jan 25, 2026) per the applicable grants.
- Filing: Reported on 2026-01-26 covering transactions from 2026-01-22 through 2026-01-25. Form 4s are generally due within two business days of a transaction; the 01-22 award appears reported four days later — review the official filing for any lateness notation.
Context
- These entries show option exercises and RSU awards, with shares withheld to cover tax obligations (a common administrative step). The exercises were reported with a $0.00 exercise price in the filing entries; the cash impact to the insider comes from taxes covered via share withholding (~$82.6K).
- Awards (RSUs) vest over multi-year schedules and do not indicate immediate sale or market sentiment by themselves. This filing is administrative in nature (exercises + tax withholding + multi-year RSU grants) rather than an open-market purchase or sale.
Insider Transaction Report
Form 4
Serafin Andrew
CHIEF STRATEGY OFFICER
Transactions
- Exercise/Conversion
Common Stock
2026-01-24+2,500→ 2,500 total - Tax Payment
Common Stock
[F1]2026-01-24$36.82/sh−1,116$41,091→ 1,384 total - Exercise/Conversion
Common Stock
2026-01-25+2,600→ 2,600 total - Tax Payment
Common Stock
[F1]2026-01-25$36.82/sh−1,126$41,459→ 1,474 total - Award
Stock Option
[F2]2026-01-22+42,600→ 42,600 totalExercise: $36.76Exp: 2036-01-22→ Common Stock (42,600 underlying) - Award
Restricted Stock Units
[F3]2026-01-22+12,200→ 12,200 total→ Common Stock (12,200 underlying) - Exercise/Conversion
Restricted Stock Units
[F4]2026-01-24−2,500→ 5,000 total→ Common Stock (2,500 underlying) - Exercise/Conversion
Restricted Stock Units
[F5]2026-01-25−2,600→ 7,800 total→ Common Stock (2,600 underlying)
Footnotes (5)
- [F1]Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date.
- [F2]The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
- [F3]The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
- [F4]This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
- [F5]This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
Signature
/s/ Christian Ulrich, Attorney-in-Fact|2026-01-26
Documents
Issuer
Harmony Biosciences Holdings, Inc.
CIK 0001802665
Entity typeother
Related Parties
1- filerCIK 0001821460
Filing Metadata
- Form type
- 4
- Filed
- Jan 25, 7:00 PM ET
- Accepted
- Jan 26, 4:48 PM ET
- Size
- 19.4 KB